Business Context and Reporting Period
This Form 6-K filing by GSK plc (the "Company") reports a transaction in its own shares for the month of November 2025. The filing details a share repurchase executed on November 12, 2025, acting through BNP Paribas SA as the broker. The transaction is part of an existing buyback programme established under a non-discretionary agreement announced on September 30, 2025.
Key Financial Metrics and Transaction Details
The filing focuses exclusively on capital structure changes via share repurchases and does not report operational financial metrics such as revenue, profit, cash flow, or debt levels.
- Shares Purchased: 167,000 ordinary shares of 31½ pence each.
- Price Range: Lowest price paid was 1,805.50p; highest price paid was 1,827.00p.
- Average Price: Volume-weighted average price paid was 1,813.49p.
- Treasury Holdings: Following this purchase, the Company holds 256,127,844 ordinary shares in treasury.
- Shares in Issue: 4,059,300,530 ordinary shares (excluding Treasury shares).
- Voting Rights: Treasury shares represent 6.31% of total voting rights.
- Cumulative Buyback: Since September 30, 2025, the Company has purchased 8,663,000 ordinary shares.
Material Changes
The primary material change reported is the reduction of shares in issue and the increase in treasury stock. The filing does not provide comparative financial data against prior periods as it is a transactional report rather than a periodic financial statement. The purchase was executed across multiple trading venues, including BATE, CHIX, and XLON.
Guidance, Outlook, and Risks
The filing contains no new financial guidance, outlook, or management commentary regarding operational performance. It includes a standard cautionary statement regarding forward-looking statements, noting that actual results may differ materially from projections due to risks described in the Company's Annual Report on Form 20-F for 2024 and Q3 Results for 2025. No unusual items or contingencies were disclosed in this specific filing.
Investor Verification Checklist
- Verify the total number of shares held in treasury (256,127,844) against the latest Form 20-F or quarterly reports.
- Confirm the remaining capacity under the existing buyback programme announced on September 30, 2025.
- Review the "Risk Factors" section of the 2024 Annual Report on Form 20-F for context on the forward-looking statement disclaimer.
- Check the current market price of GSK shares to assess the premium or discount of the repurchase price (1,813.49p VWAP) relative to the market close on November 12, 2025.